Alnylam Pharmaceuticals, Inc. vs DuPont de Nemours Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while DuPont de Nemours Inc trades at $144.26 (market cap $19.12B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DD | |
|---|---|---|
Market Cap | $29.03B | $19.12B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $154.59 |
52-Week Low | $205.48 | $90.24 |
Enterprise Value | $26.99B | $20.50B |
Dividend Yield | — | 1.7% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →